Is your post related to PRTA's amyloidosis announcement? I have been considering a position and suspect the aftermarket bounce of ~2 dollars is not warranted and may not carry over to regular hours on this announcement alone. I don't remember if it was the amyloidosis that you found more interesting or the collaboration with Roche for Parkinson’s.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.